Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 19/20 | 0.61 |
| ▸ | BCL2 | P10415 | 11/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 11/20 | 0.61 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.61 |
| ▸ | BCL2A1 | Q16548 | 8/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | LDHB | P07195 | 1/20 | 0.41 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13018809 | 0.76 | BCL2L1 (0.55) | BCL2L1BCL2MCL1BCL2L2BCL2A1 | |
| SCHEMBL2622283 | 0.76 | BCL2L1 (0.60) | BCL2L1BCL2MCL1BCL2L2BCL2A1 | |
| Apogossypol SCHEMBL2513478 | 0.76 | BCL2L1 (1.00) | BCL2L1BCL2MCL1BCL2L2BCL2A1 | |
| Apogossypol SCHEMBL29467534 | 0.76 | BCL2L1 (1.00) | BCL2L1BCL2MCL1BCL2L2BCL2A1 | |
| Apogossypol SCHEMBL29353524 | 0.76 | BCL2L1 (1.00) | BCL2L1BCL2MCL1BCL2L2BCL2A1 | |
| SCHEMBL14995971 | 0.76 | BCL2L1 (0.59) | BCL2L1BCL2MCL1BCL2L2BCL2A1 | |
| SCHEMBL14995996 | 0.76 | SMN1; SMN2 (0.41) | BCL2L1BCL2MCL1BCL2L2BCL2A1 | |
| SCHEMBL14958609 | 0.75 | MCL1 (0.87) | BCL2L1BCL2MCL1BCL2L2BCL2A1 | |
| SCHEMBL354203 | 0.75 | BCL2L1 (0.69) | BCL2L1BCL2MCL1BCL2L2BCL2A1 | |
| SCHEMBL10130333 | 0.75 | BCL2L1 (0.42) | BCL2L1BCL2MCL1BCL2L2BCL2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937193-B2 | Apogossypolone derivatives as anticancer agents | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-01-20 | — | — | US | disclosed |
| US-8455540-B2 | Gossypol and apogossypol derivatives, preparation thereof and uses thereof | UNIVERSITE DU MAINE (LE MANS) (FR) | 2013-06-04 | — | — | US | disclosed |
| US-8455540-B2 | Gossypol and apogossypol derivatives, preparation thereof and uses thereof | UNIVERSITE DU MAINE (LE MANS) (FR) | 2013-06-04 | — | — | US | disclosed |
| US-8436207-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2012-01-19 | — | — | US | disclosed |
| US-8039668-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110112112-A1 | APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-05-12 | — | — | US | disclosed |
| US-20100331398-A1 | DERIVES DU GOSSYPOL ET DE L'APOGOSSYPOL, LEURS PREPARATIONS ET LEURS APPLICTIONS | UNIVERSITE DU MAINE (LE MANS) (FR) | 2010-12-30 | — | — | US | disclosed |
| US-20100331398-A1 | DERIVES DU GOSSYPOL ET DE L'APOGOSSYPOL, LEURS PREPARATIONS ET LEURS APPLICTIONS | UNIVERSITE DU MAINE (LE MANS) (FR) | 2010-12-30 | — | — | US | disclosed |
| WO-2010120943-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112112-A1 | APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS | CYP17A1, HSD17B7, CYP27A1 | BCL2L1 195/4885BCL2 142/4885MCL1 34/4885 |
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | HAX1, PRDX1, APOL1 | BCL2L1 49/4885BCL2 30/4885MCL1 629/4885 |
| US-20100331398-A1 | DERIVES DU GOSSYPOL ET DE L'APOGOSSYPOL, LEURS PREPARATIONS ET LEURS APPLICTIONS | LSS, GRHPR, NR1H3 | BCL2L1 1749/4885BCL2 3236/4885MCL1 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.